BioStock: Cereno’s CIPO comments on strong IPR position

Patent protection is vital for all companies in the life science industry, and Swedish biotech Cereno Scientific is no exception. The company has been successful in gaining patent approvals during H2 2022 for its cardiovascular disease treatment candidates. BioStock spoke with Jonas Faijerson Säljö, Chief Intellectual Property Officer (CIPO) at Cereno Scientific, to learn more about the recent IP-news and the value of patents for the company.

Read the interview with Jonas Faijerson Säljö at biostock.se:

Cereno’s CIPO comments on strong IPR position - BioStock

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/